The 7-valent pneumococcal conjugate vaccine (PCV7) is currently being introduced in the vaccine schedule of over 90 countries around the world. After the introduction of the PCV7 vaccine in the United States, a reduction of more than 90% of invasive pneumococcal disease (IPD) was reported in vaccinated children under the age of 5 years. Similar findings were reported from other countries. A reduction in community-acquired pneumonia (CAP) of >40% has also been reported. In children under the age of 5 years, the number of primary medical visits and antibiotic usage for acute otitis media (AOM) decreased by more than 40%. In adults over 65 years of age a significant reduction of 90% in IPD caused by PCV7 serotypes was reported as well. However, after the introduction of PCV7 there were reports of increase of serotypes not included in the vaccine, such as serotype 19A in various Streptococcus pneumoniae-related diseases such as invasive disease, AOM and pneumonia. In addition, serotypes 1, 5, 7F and 19A were more prevalent in complicated cases of CAP. Recently, new vaccines covering additional serotypes such as the 10-valent pneumococcal conjugate vaccine (PCV10) and 13-valent pneumococcal conjugate vaccine (PCV13) were introduced, and are expected to reduce S. pneumoniae-related diseases furthermore. (Biomed J 2012;35:450-56) 
S treptococcus pneumoniae remains an important cause of serious illness such as pneumonia, meningitis, bacteremia among children and adults worldwide. It is also a major cause of sinusitis and acute otitis media (AOM). [1] In double-blind randomized case-control clinical trials, the 7-valent pneumococcal conjugate vaccine (PCV7) was demonstrated to be efficacious and safe against invasive pneumococcal disease (IPD). In adition, PCV7 was demonstrated to prevent 20-37% of community-acquired alveolar pneumonia in children and approximately 56% of acute otitis media caused by serotypes in included in PCV7. [1] In 2000, a 7-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV7; Prevnar, Wyeth) was licensed by the Food and Drug Administration (FDA) for use among infants and young children in the United States. [2] Since its introduc-tion in North America, PCV7 has been licensed in over 90 countries and has contributed to a massive decline in diseases caused by S. pneumoniae. [1] However, after PCV7 introduction several reports emerged on the increased incidence of other serotypes not included in the PCV7 such as serotype 19A in IPD and in AOM. [3] Moreover, the role of additional non-PCV7 vaccine serotypes, mainly serotypes 1, 3, 5, and 7F was shown both in invasive diseases and in mucosal diseases such as community-acquired pneumonia (CAP) and AOM. [4] [5] [6] [7] [8] Recently two new broader spectrum vaccines were introduced: 1) A 10-valent vaccine conjugated to a D protein obtained from Haemophilus (the innovative PHiD-CV) contains the 7 serotypes included in PCV7 and in addition serotypes 1, 5 and 7F; 2) the 13-valent pneumococcal polysaccharideprotein conjugate vaccine (PCV13) containing the 7 serotypes included in PCV7 and 6 additional pneumococcal conjugate serotypes including 1, 3, 5, 6A, 7F, and 19A. These vaccines are expected to increase the covarage of pneumococcal disease and to reduce significantly more the burden of IPD, AOM and CAP world wide.
The effect of PCV7 on invasive disease
The introduction of PCV7 into routine infant immunization programs has led to the near eradication of vaccine-serotype IPD in vaccinated children as well as in older children and adults, through herd protection. [9] [10] [11] Data from different studies show that the incidence of IPD due to PCV7 vaccine serotypes in children < 5 years of age has declined by > 90%. The rate of invasive pneumococcal disease for children under 2-years old declined by 76% by 2007, compared with prevaccine rates; the decline for infections caused by serotypes included in the vaccine was 100%. [12] Although Afro-American children remain at higher risk of IPD, the introduction of childhood pneumococcal vaccination has reduced the racial disparity in incidence of pneumococcal disease. [13] Moreover, after the introduction of PCV7, there has been a significant decline in IPD in adults, in particular in older adults (>65 years old). Data from the United States show a 73% reduction in IPD due to the PCV7 serotypes in adults 65 years of age and older. The absolute number of cases prevented by this indirect effect of PCV7 is actually estimated to be larger than the direct effect, which makes universal vaccination highly cost effective. [12] The reductions were due to decreases in vaccine-type disease (92%) and are thought to be related to reduced transmission of vaccine serotype among children, a phenomenon named herd protection (immunity), which can also be called indirect effect. [14] Thus, in many areas of the United States, substantial reductions in invasive pneumococcal infections occurred despite the shortage of PCV7 beginning in the fall of 2001-2002, which may have modified the reduction in cases. These reduction rates were also observed in other countries such as Europe, Canada and Australia after the introduction of PCV7 to their vaccine schedules. [15] 
Serotypes replacement after the introduction of PCV7
Recent reports have pointed out an increase in the non-vaccine serotypes. [16] In 2008, a total of 61% of IPD cases among children aged < 5 years were attributable to the serotypes covered in PCV13, with serotype 19A accounting for 43% of cases; PCV7 serotypes caused < 2% of cases. Three of the six additional serotypes, (19A, 7F, and 3) accounted for 99% of IPD cases, serotypes 1 and 5 together caused 0.6% of cases, and serotype 6A caused 0.6% of cases. In the age group ≥ 5 years, the serotypes included in PCV7 and PCV13 caused 4-7%, and 43-66% of IPD cases, respectively. Following routine PCV7 use, the incidence of IPD caused by penicillin-resistant strains decreased by 57% overall and by 81% among children aged < 2 years. [16] Invasive pneumococcal disease caused by penicillin-nonsusceptible non-PCV7 serotypes increased, and most of the resistant infections are now caused by serotype 19A. [17] Between 2007 and 2009 following PCV7 implementation in Spain, a surveillance study was undertaken in order to assess all isolates from invasive disease. [18] The most common serotypes isolated from IPD cases were serotypes included in the PCV13 (but not in PCV7): 19A (26.1%), 5 (18.8%), 7F (8.5%) and 3 (3.9%) pointing out the benefits of introducing this vaccine in Spain. [19] In a 2-year Spanish survey on invasive disease, 19A was the most common encountered serotype. [18] In the Navajo population, between 1995 and 2006, in an active surveillance system which included 1508 cases of IPD the total number of cases decreased from 67 in 1995-1997 to 51 cases in the years following PCV7 introduction. [20] There was no change in the nonvaccine type (NVT) in children in the post vaccine era. Rates increased for serotypes 1, 3, 5, 7F, 19A, 18B. In infants under the age of 2 months no cases with serotype included in the PCV7 was reported with no replacement by NVT disease. [20] A combined study of four European countries was done after PCV7 introduction in Europe. [21] Different countries have implemented vaccination in various time periods, but all consider the 7 serotypes contained in the vaccine as being responsible for 68% to 77% of IPD in children under 5 years of age. During 2005 and 2006 the incidence of IPD started to increase due to NVT both in the under 5-year-old population and children 5-14 years old. [22] The most encountered serotypes were: 1, 7F and 19A considered to be nonvaccine serotypes. However, for children under the age of 5 years, serotype 1 started to become more prevalent before PCV7 introduction. Moreover, two peak point increases betwen 1996-2002 and 2005-2006 were reported. For the 5-14 years old group the major cause of IPD in 50% of cases was serotype 1 in 2005-2006. For serotype 7F most cases occured in the age group under 5 years and increased mostly during 2004-2006 except in Spain. For 2005-2006 it increased mostly in Spain but less so in England and Wales. With regard to serotype 19A incidence of IPD actually doubled in the group of the under 5 years of age. [21] While for countries having adopted PCV7, the prevalence of serotypes 1, 7F and 19A increased, only serotype 1 increased in England and Wales. Antimicrobial resistance pattern showed high resistance rates for Spain, Belgium and France after the introduction of PCV7. The resistance rates increased to 86% for penicillin and around 77% for macrolides. There may be other explanations besides that of PCV7 selective pressure such as the overuse of macrolides with selective pressure toward more antibiotic resistant isolates especially for serotype 19A. Another explanation is the secular trend or the cyclical trend of serotype 1.
A study from Portugal on invasive disease during 2006-2008 reported that serotypes included in the PCV7 accounted for only 17% of the cases. The most frequent causes of IPD were due to serotypes 1, 7F and 19A. [23, 24] In an observational study from Dallas, TX, USA, conducted over a period of 8 years (1999-2008) and comparing the two periods before and after PCV7 introduction, a decrease in IPD during 2002-2008 was reported. However, between 2006 and 2008 the incidence of IPD started to increase. Serotype 19A was the one that increased significantly and its resistance to antibiotic drugs such as penicillin and cefotaxime significantly increased as well. The increase in the resistance rate of serotype 19A was due to the introduction of clonal complex cc-156 and cc-320 which emerged at the same time as 19A resistance to penicillin and cefotaxim. [25] The effect of PCV7 on CAP Six trials tested the effect of vaccine on clinically and radiologically diagnosed CAP. In the Northern California trial, vaccination reduced episodes of pneumonia confirmed by radiography by 30%. [26] A study among children without HIV infection in South Africa showed that the vaccine reduced the first episodes of alveolar pneumonia by 25% among fully immunized infants. [27] In the Gambia, vaccination reduced radiologically confirmed pneumonia by 37%, including a reduction of hospital admissions and all-cause mortality by 15% and 16%, respectively. [28] The American Indian trial pneumonia results were inconclusive the performance of the vaccine may vary in accordance to many aspects including epidemiological and population characteristics. [29] Subsequently an investigational 11-valent conjugate vaccine reduced alveolar consolidation confirmed pneumonia by 23% in the Philippines [30] and a 10-valent conjugate including serotypes conjugated to Haemophilus protein D has been reported to reduce pneumonia in children in South and Central America by 25%. [31] Since the introduction of PCV7, a reduction in CAP of 39% and primary physician visits due to AOM of 42% were reported. [32, 33] Beside the serotypes included in PCV7, the most common serotypes causing IPD are 1 and 5, prevalent mainly in developing countries, [34, 35] and particularly in Asia [36] where the incidence rates of these diseases are significantly higher compared with North America and Europe. [37, 38] These serotypes have also been reported in outbreaks of IPD and CAP in both children and adults. [39] [40] [41] Serotype 1 is common in children > 2 years of age and in complicated pneumonia cases. [42] Following the introduction of the PCV7, significant impact on CAP was demonstrated showing up to 39% reduction in all-cause pneumonia. [43] However, increasing rates of empyema have been reported from various countries mainly caused by serotypes 1, 3, 5, 7F and 19A (serotypes not included in the vaccine). [4] The disease potential of such serotypes as 1, 5 and 7F have been reported significantly more often in IPD, CAP and AOM. [44] In Poland, the two infant doses schedule of PCV7 was found to be efficacious for reduction of CAP in children. [45] A significant impact of pediatric vaccination on reduction in hospitalization for alveolar pneumonia in adults in the US has been recently shown and more than 90% of the reduction in hospitalization for pneumonia attributable to the vaccine is the reduction in disease in adults due to herd protection. [46] The effect of PCV7 on AOM In a randomized clinical trial conducted in Finland in which the bacterial etiology of AOM was determined by myringotomy, the efficacy of PCV7 in preventing culture-confirmed, vaccine serotype AOM episodes was 57% (95% CI, 44-67%): the overall net reduction in AOM caused by any pneumococcal serotype was 34% (95% CI, 21-45%). Overall, PCV7 prevented 6-7% of all AOM episodes in the clinical trials; [47] reductions also were observed for the outcomes of frequent otitis media (9%) and tympanostomy tube placement (20%). [48] Following the introduction of PCV7 in the United States, a reduction of 20% in otitis media visit rates in children under 2 years of age was reported. This decline represented 246 fewer otitis media visits per 1000 children in this age group annually. [49] These finding were similar in a population base study in Quebec reporting a reduction of physician claims for otitis media attributable to PCV-7 of 13.2%. [50] In Australia, 2.5 years after the introduction of PCV7 a significant adjusted decrease in myringotomy with ventilation tube insertion in children aged under 1, 1-2, and older than 2-years old of 23%, 16%, and 6%, respectively, [51] was reported. Similar findings were reported in Tennessee in children under 2 years of age with reductions of 17% in AOM rates and 23% in pressure-equalizing tube insertions. In New York decline rates of 16% and 23% were reported in AOM and pressure-equalizing tube insertions when the 2000-2001 birth cohort (after PCV7 introduced) was compared to the 1998-1999 birth cohort (pre-PCV7 vaccination period). [52] Reduction in hospitalization rates in children under 2 years of age with AOM was reported from Liguria, Italy. [53] After the introduction of PCV7 into the national immunization program in United States, rates of ambulatory visits and antibiotic prescriptions attributable to AOM decreased by 42.7% and 41.9%, respectively. [54] Total estimated nation-al direct medical expenditures for AOM-related ambulatory visits and antibiotic prescriptions for children younger than 2 years of age decreased from an average of $1.41 billion during 1997 to 1999 to $0.95 billion in 2004 (32.3% reduction). [54] This reduction was sustained and a 36% reduction in antibiotic prescription was also reported after 6 years of PCV7 usage in the United states. [55] In a study of Hoberman et al. [56] it was shown that the proportion of the S. pneumoniae that were vaccine serotypes declined progressively while there was an increase of penicillin non susceptible isolates with 19A being one of the most important. Also it was shown that the penicillin nonsusceptible isolates belonged to 19A. [56] The effect of PCV7 on nasopharyngeal carriage Pneumococcal conjugate vaccines have been shown to reduce the risk of carriage and transmission of vaccine-type strains among vaccines and their household members. PCV7 reduces the acquisition of vaccine-type strains but increases the risk for carriage of nonvaccine serotype. Several studies have found an increase in nasopharyngeal colonization by nonvaccine or replacement serotypes of S. pneumoniae among children who received a conjugate pneumococcal vaccine. [57, 58] In addition to the PCV7, the 9-valent vaccine conjugated to CRM197 reduced nasopharyngeal pneumococcal carriage in toddlers, especially in those less than 36 months of age. [59] In a study in the pre-PCV7 period, looking at the carriage of S. pneumoniae serotypes in children < 5 years old with CAP versus healthy controls it was found that serotypes 1, 5, 7F, 9V, 14, 19A and 22F have a significant relative higher disease potential than serotypes 6A, 6B, 23A and 35B to cause CAP. [44] The authors pointed out that the carriage rate was the highest in the 6-17-month-old group. The article suggested that expanding the number of the serotypes in a 13-valent vaccine would provide significantly higher coverage of the more virulent serotypes. [44] In the northern part of Europe, studies looking at carriage were conducted before and after the implementation of a 2 + 1 schedule of PCV7 vaccination. In this study 1,213 children were included before and 602 after implementation of PCV7. Despite a decrease in the serotype covered by the vaccine the overall carriage rate remained high. Serotypes included in the PCV7 were carried by 12.7% of the 237 children who had received at least two doses of vaccine and by 23.3% of the 365 who received at least one dose of vaccine. Carriage decreased significantly in the group that received at least two doses of vaccine. There was also a decrease of the serotypes included in the vaccine including serotype 6A, except for serotypes 4 and 19F. However the prevalence of 19A remained the same. [60] In a study by Hoberman et al., where nasopharyngeal samples were obtained from chil-dren aged 6-23 month with AOM divided into three groups pre-PCV7, immediately post-PCV7 and late post-PCV7, the prevalence of the PCV7 serotypes declined progressively while the non-PCV7 serotypes which were not penicillin nonsusceptible increased, mainly for serotype 19A, 4% and 25.9%, respectively. [56] 
Emergence of the new serotypes
Serotype 6C is considered to be one of the replacement serotypes in the post PCV7 era despite the fact that it may have originated 27 years ago. Recently a new serotype, 6D was reported. Serotype 6C originally mutated from 6A and serotype 6D originally mutated from serotype 6B. [61] A specific anti-serum was developed to differentiate among the 6 serogroups (A, B, C, and D). This specific antibodies test was validated using 189 isolates of serogroup 6 obtained from a surveillance study from the United States and Israel. [61] Millar et al., performed a study in the Navajo population in order to assess the epidemiology of serotype 6C before and after PCV7 introduction. They analysed the 6A serotypes using conventional methods to study S. pneumoniae isolates obtained from invasive disease and also triplex polymerase chain reaction to solve the problem of serotypes 6A and 6C. Serotype 6C had a mean annual incidence of 0.3% and 76% of the 6A isolates causing IPD were 6C and nearly all were found in adults. [62] Several studies reported that serotype 6C also circulated in the era pre-PCV7 introduction but was serotyped as serotype 6A by the Quellung reaction. In a study performed before PCV7 introduction including over 1,396 presumed serotype 6A isolates isolated from blood or cerebrospinal fluid, middle year fluid (MEF) nasopharynx (NP) and conjunctiva from children, serotype 6C constituted 8.2% of the presumed serotype 6A isolates and had the following distribution, 7.4% from blood, 3.1% from MEF, 6.0% from conjunctiva, 9.8% from NP cultures. [63] The newly 11E arises from antigenically similar 11A progenitors, and each strain contains a distinct wcjE suggesting that it is not transmitted among hosts.It may independently arise during infection after initial colonization with a 11A progenitor serotype. More studies are needed before we could make a clear statement. [64] The pneumococcus is a naturally transformable organism and it has the ability to take up the DNA from other strains and incorporate it into its own genome.
Except for 19A the most common ST in 15B/C strains remains 199 but the emergency of 15B/C has been due to multiple unrelated clones and there is also a marked clonal diversity between different years of study as were 2004-2007. [65] Broader spectrum pneumococcal conjugated vaccines A 10-valent vaccine conjugated to a D protein obtained from Haemophilus (the innovative PHiD-CV) was developed. This vaccine contains the 7 serotypes included in PCV7 and in addition serotypes 1, 5 and 7F. It has a robust clinical profile to offer broad protection against IPD and efficacy similar to that of PCV7 for CAP. In addition, this vaccine demonstrated significantly better efficacy than PCV7 for AOM in children. [66] An even broader spectrum PCV was introduced recently worldwide, the PCV13 containing the 7 serotypes included in PCV7 and 6 additional pneumococcal conjugate serotypes including 1, 3, 5, 6A, 7F, and 19A. The addition of these 6 serotypes will potentially increase the percentage of vaccine-preventable IPD cases to 90% or more in most regions of the world. [65] PCV13 is currently replacing PCV7 in North America, Western Europe, Israel and other countries world wide.
Conclusions
Since the licensure of PCV7 in the United States in 2000, its effectiveness in preventing IPD in infants has been clearly observed. Data from different studies show that the incidence of IPD due to PCV7 vaccine serotypes in children < 5 years of age has declined by > 90%. These reduction rates were also observed in other countries such as Europe, Canada and Australia after the introduction of PCV7 to their vaccine schedules. In addition, reduction in CAP and otitis media in children < 5 years of age were reported from different countries using PCV7. The impact of PCV7 on nasopharyngeal carriage and the resulting indirect effect on herd protection contribute significantly to the cost effectiveness of the vaccine. There was a statistically significant decline in IPD in adults aged 20 years and older after the introduction of PCV7, the most significant in older adults (>65 years old).
However, recent data from United States and Europe have shown increases in IPD caused by non-PCV7 serotypes in both infants and adults. This increase in non-PCV7 vaccine serotypes was mainly observed due to serotype 19A which is characterized by its antibiotic resistance profile. Thus, the dual effect of high antibiotic usage in the community and the usage of PCV7 facilitates increase rates of this serotype worldwide. In addition increased rates of complicated pneumonia in children due to serotypes 1, 3, 5, 7F, and 19A in Europe and North America have been reported.
A broader protection of PCV13 against IPD, pneumonia, and otitis media is anticipated compared to PCV7. In addition, it is anticipated that the PCV13 vaccine will reduce nasopharyngeal carriage of the 6 additional serotypes (1, 3, 5, 6A, 7F and, 19A), and thereby extend herd immunity.
